Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers

[1]  L. Bubendorf,et al.  Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. , 2011, Human pathology.

[2]  W. Foulkes,et al.  Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade , 2011, Histopathology.

[3]  Guobin Wang,et al.  Th17 cells in cancer: help or hindrance? , 2011, Carcinogenesis.

[4]  I. Ellis,et al.  An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer , 2011, Breast Cancer Research and Treatment.

[5]  X. Chen,et al.  IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. , 2011, Biochemical and biophysical research communications.

[6]  L. Terracciano,et al.  High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients , 2010, International journal of cancer.

[7]  A. Giaccia,et al.  Hypoxia, inflammation, and the tumor microenvironment in metastatic disease , 2010, Cancer and Metastasis Reviews.

[8]  A. Tzankov,et al.  Comment on “Cutting Edge: Depletion of Foxp3+ Cells Leads to Induction of Autoimmunity by Specific Ablation of Regulatory T Cells in Genetically Targeted Mice” , 2010, The Journal of Immunology.

[9]  H. Putter,et al.  The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer , 2010, Clinical Cancer Research.

[10]  U. Güth,et al.  Breast cancer with non-inflammatory skin involvement: current data on an underreported entity and its problematic classification. , 2010, Breast.

[11]  Yanping Zhang,et al.  Tumor Microenvironments Direct the Recruitment and Expansion of Human Th17 Cells , 2009, The Journal of Immunology.

[12]  A. Rudensky,et al.  Cutting Edge: Depletion of Foxp3+ Cells Leads to Induction of Autoimmunity by Specific Ablation of Regulatory T Cells in Genetically Targeted Mice1 , 2009, The Journal of Immunology.

[13]  C. Caux,et al.  Differences in tumor regulatory T-cell localization and activation status impact patient outcome. , 2009, Cancer research.

[14]  A. Goldhirsch,et al.  Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. , 2009, Breast.

[15]  I. Ellis,et al.  The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. , 2009, European journal of cancer.

[16]  R. Matkowski,et al.  The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. , 2009, Anticancer research.

[17]  P. Vaupel,et al.  Tumor hypoxia and malignant progression. , 2009, Methods in enzymology.

[18]  S. Ménard,et al.  FOXP3 expression and overall survival in breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[20]  C. Akdis,et al.  Unique Phenotype of Human Tonsillar and In Vitro-Induced FOXP3+CD8+ T Cells1 , 2009, The Journal of Immunology.

[21]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  K. Allison,et al.  Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target , 2008, Modern Pathology.

[23]  M. Carini,et al.  Prognostic role of histological necrosis for nonmetastatic clear cell renal cell carcinoma: correlation with pathological features and molecular markers. , 2008, The Journal of urology.

[24]  G. Keren,et al.  Hypoxia controls CD4+CD25+ regulatory T‐cell homeostasis via hypoxia‐inducible factor‐1α , 2008, European journal of immunology.

[25]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[26]  B. Chauffert,et al.  Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.

[27]  T. Curiel.  Regulatory T cells and treatment of cancer. , 2008, Current opinion in immunology.

[28]  M. Roncarolo,et al.  Is FOXP3 a bona fide marker for human regulatory T cells? , 2008, European journal of immunology.

[29]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[30]  S. Dermime,et al.  FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy , 2008, BMC Cancer.

[31]  C. Pilarsky,et al.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. , 2007, Cancer research.

[32]  C. Morrison,et al.  FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene , 2007, Cell.

[33]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[35]  A. Ribeiro-Silva,et al.  Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. , 2006, Clinics.

[36]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[37]  T. Rowlands,et al.  Cadherins and catenins in breast cancer. , 2005, Current opinion in cell biology.

[38]  W. Landuyt,et al.  The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy , 2005, BMC Cancer.

[39]  A. Mackensen,et al.  Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. , 2004, Cancer research.

[40]  Ronald Simon,et al.  Tissue microarrays in drug discovery , 2003, Nature Reviews Drug Discovery.

[41]  W. Symmans,et al.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  J. M. de Andrade,et al.  Lymphocyte Subpopulations in Patients with Advanced Breast Cancer Submitted to Neoadjuvant Chemotherapy , 2000, Tumori.

[43]  J. Banchereau,et al.  Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. , 1999, Cancer research.

[44]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[45]  S. Ménard,et al.  Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  L. Filgueira,et al.  The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor‐infiltrating lymphocytes , 1994, International journal of cancer.

[47]  J. Raus,et al.  Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. , 1992, Anticancer research.

[48]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[49]  B. Chauffert,et al.  Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy , 2010, Breast Cancer Research and Treatment.

[50]  M. S. Abdullah,et al.  Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. , 2010, Cancer immunity.

[51]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  M. Mihm,et al.  Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. , 2009, Cancer immunity.

[53]  G. Sakamoto,et al.  Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast , 2004, Virchows Archiv.

[54]  D. Ferguson,et al.  Intraepithelial lymphocytes and macrophages in the normal breast , 2004, Virchows Archiv A.

[55]  T. Whiteside,et al.  Functional and phenotypic analysis of tumor‐infiltrating. Lymphocytes isolated from human primary and metastatic. Liver tumors and cultured in recombinant interleukin‐2 , 1989, Cancer.